docetaxel anhydrous has been researched along with arginine in 11 studies
| Studies (docetaxel anhydrous) | Trials (docetaxel anhydrous) | Recent Studies (post-2010) (docetaxel anhydrous) | Studies (arginine) | Trials (arginine) | Recent Studies (post-2010) (arginine) |
|---|---|---|---|---|---|
| 12,110 | 3,216 | 6,920 | 46,388 | 1,688 | 11,176 |
| 12,110 | 3,216 | 6,920 | 1,016 | 177 | 64 |
| Protein | Taxonomy | docetaxel anhydrous (IC50) | arginine (IC50) |
|---|---|---|---|
| Cationic amino acid transporter 3 | Homo sapiens (human) | 283 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (9.09) | 18.2507 |
| 2000's | 2 (18.18) | 29.6817 |
| 2010's | 8 (72.73) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Feng, Y; Shen, Y; Shi, J; Tang, L; Tian, Y; Tu, J; Zhang, J; Zhao, J | 1 |
| Liang, YY; Lin, QM; Ma, D; Xue, W; Zhang, LM | 1 |
| Akande, T; Bomalaski, JS; Diaz, M; Dutia, MP; Gandara, DR; Gong, IY; Kelly, K; Lara, PN; Li, T; Mahaffey, N; Pan, CX; Semrad, T; Thomson, JA; Tomlinson, BK | 1 |
| Cao, Y; Du, Y; Feng, Y; Jin, F; Liu, F; Wang, Q; Zhang, Y | 1 |
| Chang, SF; Godec, A; Hawkins, WG; Hirbe, AC; Prudner, BC; Rathore, R; Robinson, AM; Van Tine, BA | 1 |
| Ghaemmaghami, M; Jett, JR | 1 |
| Belani, CP; Calvo, AR | 1 |
| Bunn, PA; Simon, GR | 1 |
| Pagani, M | 1 |
| Brown, JB; Kadoyama, K; Kuwahara, A; Okuno, Y; Sakaeda, T; Yamamori, M | 1 |
5 review(s) available for docetaxel anhydrous and arginine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
New agents in the treatment of small cell lung cancer.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Drugs, Investigational; Gemcitabine; Humans; Immunologic Factors; Irinotecan; Lung Neoplasms; Menogaril; Paclitaxel; Taxoids; Teniposide; Topotecan; Treatment Outcome; Vinblastine; Vinorelbine | 1998 |
Lung cancer: therapeutic options for stage IV and recurrent NSCLC.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Deoxycytidine; Docetaxel; Etoposide; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Multicenter Studies as Topic; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Randomized Controlled Trials as Topic; Risk Factors; Survival Rate; Taxoids; Teniposide; Treatment Outcome; Vinblastine; Vinorelbine | 2001 |
Taxanes in the treatment of advanced (stage III and IV) non-small cell lung cancer (NSCLC): recent developments.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Docetaxel; Etoposide; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Microtubules; Multicenter Studies as Topic; Neoadjuvant Therapy; Organoplatinum Compounds; Paclitaxel; Palliative Care; Podophyllotoxin; Randomized Controlled Trials as Topic; Salvage Therapy; Survival Analysis; Taxoids; Teniposide; Treatment Outcome; Vinblastine; Vinorelbine | 2003 |
The complex clinical picture of presumably allergic side effects to cytostatic drugs: symptoms, pathomechanism, reexposure, and desensitization.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Asparaginase; Carboplatin; Cisplatin; Cytostatic Agents; Desensitization, Immunologic; Docetaxel; Drug Hypersensitivity; Humans; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Procarbazine; Risk Factors; Taxoids; Teniposide | 2010 |
1 trial(s) available for docetaxel anhydrous and arginine
| Article | Year |
|---|---|
Phase I Trial of Arginine Deprivation Therapy with ADI-PEG 20 Plus Docetaxel in Patients with Advanced Malignant Solid Tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arginine; Docetaxel; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Hydrolases; Male; Neoplasm Staging; Neoplasms; Polyethylene Glycols; Taxoids; Treatment Outcome | 2015 |
5 other study(ies) available for docetaxel anhydrous and arginine
| Article | Year |
|---|---|
Arginine-stabilized mPEG-PDLLA (50/50) polymeric micelles of docetaxel by electrostatic mechanism for tumor-targeted delivery.
Topics: Animals; Animals, Inbred Strains; Antineoplastic Agents; Arginine; Carcinoma, Lewis Lung; Docetaxel; Dogs; Drug Carriers; Drug Compounding; Drug Delivery Systems; Drug Stability; Female; Male; Metabolic Clearance Rate; Mice; Micelles; Neoplasm Transplantation; Particle Size; Polyesters; Polyethylene Glycols; Random Allocation; Taxoids; Tissue Distribution; Toxicity Tests, Acute | 2015 |
A star-shaped porphyrin-arginine functionalized poly(L-lysine) copolymer for photo-enhanced drug and gene co-delivery.
Topics: Animals; Apoptosis; Arginine; Biocompatible Materials; Cell Line, Tumor; Chromatography, Gel; Docetaxel; Drug Delivery Systems; Female; Flow Cytometry; Gene Transfer Techniques; Hemolysis; Humans; Light; Magnetic Resonance Spectroscopy; Matrix Metalloproteinase 9; Mice; Particle Size; Polylysine; Porphyrins; Protein Binding; RNA, Messenger; Static Electricity; Taxoids; Transfection | 2014 |
l-arginine and docetaxel synergistically enhance anti-tumor immunity by modifying the immune status of tumor-bearing mice.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Arginine; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Dendritic Cells; Docetaxel; Drug Synergism; Female; Humans; Lymphocyte Activation; Mammary Neoplasms, Animal; Mice; Mice, Inbred BALB C; Myeloid-Derived Suppressor Cells; Taxoids; Tumor Burden; Tumor Microenvironment | 2016 |
Arginine Starvation and Docetaxel Induce c-Myc-Driven hENT1 Surface Expression to Overcome Gemcitabine Resistance in ASS1-Negative Tumors.
Topics: Animals; Arginine; Argininosuccinate Synthase; Cell Line, Tumor; Cell Membrane; Deoxycytidine; Disease Models, Animal; Docetaxel; Equilibrative Nucleoside Transporter 1; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Mice; Models, Biological; Neoplasms; Protein Binding; Protein Transport; Proto-Oncogene Proteins c-myc; Xenograft Model Antitumor Assays | 2019 |
Hypersensitivity reactions to anticancer agents: data mining of the public version of the FDA adverse event reporting system, AERS.
Topics: Adverse Drug Reaction Reporting Systems; Antineoplastic Agents; Asparaginase; Bayes Theorem; Data Mining; Docetaxel; Drug Hypersensitivity; Etoposide; Humans; Paclitaxel; Pharmacovigilance; Procarbazine; Prognosis; Taxoids; Teniposide; United States; United States Food and Drug Administration | 2011 |